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Background
Recombinant Adenovirus 5 vector (rAd5) induces potent
immune responses against recombinant antigens, but its
efficacy may be limited by anti-Ad5 neutralizing antibod-
ies and there is considerable seroprevalence in humans.
Alternative viral vectors with rare seroprevalence and sim-
ilar or higher immunogenicity compared to rAd5 are
under development.
Methods
We have generated rAd vectors derived from a rare human
serotype adenovirus, Ad 28, encoding HIV envelope
(rAd28-Env) and evaluated its ability to transduce den-
dritic cells (DC) in humans and mice. We also have exam-
ined the immunogenicity of rAd28-Env in various
immunization regimens, such as single intramuscular
injection, DNA prime/rAd boost and rAd prime/rAd boost
immunizations in mice.
Results
rAd28 tranduced human plasmacytoid DC, myeloid DC,
and monocytes efficiently and stimulated the production
of higher IFN-α and TNF secretion by these DCs than
rAd5. rAd28-Env induced comparable systemic cellular
and humoral immune responses to Ad5-Env in DNA
prime/rAd boost immunization, but it stimulated lower
levels of mucosal cellular immune responses than rAd5-
Env. However, rAd28-Env prime followed by rAd5-Env
boost regimen increased mucosal and systemic cellular
immune responses more effectively than other rAd prime/
rAd boost regimens. Furthermore, this immunization reg-
imen also stimulated potent systemic humoral immunity.
Its efficacy in protecting against SIV challenge in non-
human primates is in progress, and the status of these
studies will be described.
Conclusion
rAd28 represents a promising rare serotype vector that is
suitable for further clinical development of an HIV vac-
cine.
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